A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS

Journal of Infectious Diseases

Volumn 176, Issue 4, 1997, Pages 892-898

  Lalezari, Jacob ^a   Schacker, Tim ^f   Feinberg, Judith ^c   Gathe, Joseph ^f   Lee, Sabina ^d   Cheung, Tony ^e   Kramer, Francoise ^f   Kessler, Harold ^f   Corey, Lawrence ^f   Lawrence Drew, W ^f   Boggs, John ^b   McGuire, Brian ^f   Jaffe, Howard S ^f   Safrin, Sharon ^f  

^a Quest Clinical Research   (United States)

^b PALO ALTO MEDICAL FOUNDATION   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d Raleigh Assoc Med Specialists I   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIROLOGY; VIRUS CULTURE; WOUND HEALING;

EID: 16944362622     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516542     Document Type: Article

References (17)

1. Pottage JC Jr, Kessler HA. Herpes simplex virus resistance to acyclovir: clinical relevance. Infect Agents Dis 1995;4:115-24.
2. Balfour HH. Resistance of herpes simplex to acyclovir. Ann Intern Med 1983;98:404-6.
3. Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325:551-5.
4. Kessler HA, Hurwitz S, Farthing C, et al. Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). J Acquir Immune Defic Syndr 1996; 12:147-52.
5. Amin AR, Robinson MR, Smith DD, Swenson CF, Luque AE. Trifluorothymidine 0.5% ointment in the treatment of aciclovir-resistant mucocutaneous herpes simplex in AIDS [letter]. AIDS 1996; 10:1051-3.
6. De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonyl-methoxyalkyl derivatives of purines and pyrimidines. Antiviral Res 1987;8:261-72.
7. Hitchcock MJM, Jaffe HS, Martin JC, Stagg RJ. Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chem Chemother 1996; 7:115-27.
8. Mendel DB, Barkhimer DB, Chen MS. Biochemical basis for increased susceptibility to cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity. Antimicrob Agents Chemother 1995;39:2120-2.
9. Ho HT, Woods K.L, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJM. Intracellular metabolism of the antiherpes agent (S)-l-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 1991;41: 197-202.
10. Lalezari JP, Drew WL, Glutzer E, et al. Treatment with intravenous (S)-l-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 1994; 170:570-2.
11. Snoeck R, Andrei G, Gerard M, et al. Successful treatment of progressive mucocutaneous acyclovir- and foscarnet-resistant herpes simplex virus infection with (S)-l-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 1994; 18:570-8.
12. Snoeck R, Andrei G, DeClercq E, et al. A new topical treatment for resistant herpes simplex infections [letter]. N Engl J Med 1993;329: 968-9.
13. Safrin S, Elbeik T, Phan L, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1994;38:1246-50.
14. Cundy KC, Petty BG, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995;39:1247-52.
15. Dawson JP. Comparing treatment groups in the basis of slopes, areas-under-the-curve, and other summary measures. Drug Inform J 1994;28: 723-32.
16. Hardy WD. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. Am J Med 1992;92(suppl 2A):30S-5S.
17. Safrin S, Kemmerly S, Plotkin B, et al. Foscamet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994; 169:193-6.